Literature DB >> 12412831

Cannabidiol: an overview of some pharmacological aspects.

Raphael Mechoulam1, Linda A Parker, Ruth Gallily.   

Abstract

Over the past few years, considerable attention has focused on cannabidiol (CBD), a major nonpsychotropic constituent of cannabis. The authors present a review on the chemistry of CBD and discuss the anticonvulsive, antianxiety, antipsychotic, antinausea, and antirheumatoid arthritic properties of CBD. CBD does not bind to the known cannabinoid receptors, and its mechanism of action is yet unknown. It is possible that, in part at least, its effects are due to its recently discovered inhibition of anandamide uptake and hydrolysis and to its antioxidative effect.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12412831     DOI: 10.1002/j.1552-4604.2002.tb05998.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  113 in total

Review 1.  Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?

Authors:  Javier Fernández-Ruiz; Onintza Sagredo; M Ruth Pazos; Concepción García; Roger Pertwee; Raphael Mechoulam; José Martínez-Orgado
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

2.  HU-444, a Novel, Potent Anti-Inflammatory, Nonpsychotropic Cannabinoid.

Authors:  Christeene G Haj; Percy F Sumariwalla; Lumír Hanuš; Natalya M Kogan; Zhana Yektin; Raphael Mechoulam; Mark Feldmann; Ruth Gallily
Journal:  J Pharmacol Exp Ther       Date:  2015-08-13       Impact factor: 4.030

3.  Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression.

Authors:  G Esposito; C Scuderi; C Savani; L Steardo; D De Filippis; P Cottone; T Iuvone; V Cuomo; L Steardo
Journal:  Br J Pharmacol       Date:  2007-06-25       Impact factor: 8.739

Review 4.  The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis.

Authors:  Britta Hahn
Journal:  Schizophr Bull       Date:  2018-01-13       Impact factor: 9.306

5.  Effects of cannabidiol plus naltrexone on motivation and ethanol consumption.

Authors:  Adrián Viudez-Martínez; María S García-Gutiérrez; Ana Isabel Fraguas-Sánchez; Ana Isabel Torres-Suárez; Jorge Manzanares
Journal:  Br J Pharmacol       Date:  2018-07-01       Impact factor: 8.739

6.  A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study.

Authors:  Khalid A Jadoon; Garry D Tan; Saoirse E O'Sullivan
Journal:  JCI Insight       Date:  2017-06-15

Review 7.  Screening Medications for the Treatment of Cannabis Use Disorder.

Authors:  L V Panlilio; Z Justinova; J M Trigo; B Le Foll
Journal:  Int Rev Neurobiol       Date:  2016-03-10       Impact factor: 3.230

8.  Auditory mismatch negativity deficits in long-term heavy cannabis users.

Authors:  Patrik Roser; Beate Della; Christine Norra; Idun Uhl; Martin Brüne; Georg Juckel
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-02-02       Impact factor: 5.270

Review 9.  Medical Cannabis for Older Patients.

Authors:  Amir Minerbi; Winfried Häuser; Mary-Ann Fitzcharles
Journal:  Drugs Aging       Date:  2019-01       Impact factor: 3.923

Review 10.  Cannabinoid-based medicines for neurological disorders--clinical evidence.

Authors:  Stephen Wright
Journal:  Mol Neurobiol       Date:  2007-06-29       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.